Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

PF-06821497

Generic Name: PF-06821497

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄Cl_₂N_₂O_₅

CAS Number: 1844849-10-0

Unique Ingredient Identifier: S4L4MM20B6

Overview

PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).

Background

PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3

Recruiting

Posted: 2024/10/08

Sponsor:Pfizer

ID:NCT06629779

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Phase 3

Recruiting

Posted: 2024/08/13

Sponsor:Pfizer

ID:NCT06551324

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Phase 1

Completed

Posted: 2024/04/30

Sponsor:Pfizer

ID:NCT06392230

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Phase 1

Completed

Posted: 2023/03/14

Sponsor:Pfizer

ID:NCT05767905

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pfizer's Mevrometostat Shows Promising Results in Phase I Prostate Cancer Trial

4 months ago

Pfizer's experimental drug mevrometostat demonstrated significant efficacy in Phase I trials, reducing disease progression rates by 50% when combined with standard hormone therapy for metastatic castration-resistant prostate cancer.

Pfizer to Present Landmark Survival Data for Cancer Therapies at ASCO GU 2025 Symposium

4 months ago

Pfizer will showcase over 20 abstracts at ASCO GU 2025, including pivotal Phase 3 TALAPRO-2 trial results demonstrating significant overall survival benefits for TALZENNA-XTANDI combination in prostate cancer.

Phase III Trial MEVPRO-1 Evaluates Mevrometostat Plus Enzalutamide in mCRPC Post-Abiraterone

6 months ago

MEVPRO-1 is a phase III trial assessing mevrometostat with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) after abiraterone treatment.

Phase 3 Trials Target Advanced Prostate Cancer with Novel Therapies

8 months ago

A Phase 3 trial is underway to assess CAN-2409 immunotherapy combined with radiation for localized prostate cancer, aiming to improve disease-free survival.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy